Zura Bio Limited (NASDAQ:ZURA – Get Free Report) saw some unusual options trading on Monday. Stock investors bought 2,355 call options on the company. This is an increase of 165% compared to the average volume of 889 call options.
Analyst Upgrades and Downgrades
ZURA has been the subject of a number of research analyst reports. Wall Street Zen upgraded Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Wedbush lifted their price target on Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. William Blair initiated coverage on Zura Bio in a report on Wednesday, July 8th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, October 2nd. Finally, Guggenheim lifted their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Zura Bio currently has an average rating of “Moderate Buy” and an average price target of $17.00.
View Our Latest Analysis on ZURA
Zura Bio Price Performance
Shares of ZURA traded up $0.21 during trading hours on Monday, hitting $3.58. 2,157,734 shares of the company were exchanged, compared to its average volume of 1,336,920. The company has a market capitalization of $342.59 million, a PE ratio of -3.16 and a beta of 0.01. The firm has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $4.90. Zura Bio has a one year low of $3.25 and a one year high of $7.44.
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. Sell-side analysts expect that Zura Bio will post -0.81 EPS for the current year.
Institutional Trading of Zura Bio
Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Montanova Capital LLC lifted its stake in Zura Bio by 4.1% during the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company’s stock valued at $55,714,000 after buying an additional 376,000 shares in the last quarter. EcoR1 Capital LLC acquired a new position in shares of Zura Bio in the first quarter worth about $7,019,000. Siren L.L.C. increased its position in shares of Zura Bio by 187.3% in the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after acquiring an additional 2,434,866 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Zura Bio in the first quarter worth approximately $4,483,000. Finally, Bank of America Corp DE raised its holdings in shares of Zura Bio by 3,007.7% during the first quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after acquiring an additional 132,130 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.
About Zura Bio
Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.
Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.
Featured Articles
- Five stocks we like better than Zura Bio
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
- 4 Small-Cap Stocks With Paths to Recovery After the Fed’s September Rate Hike
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
